NO317003B1 - Anvendelse av hepariner med lav molekylvekt for fremstilling av et medikament for terapi av cerebrale odemer - Google Patents

Anvendelse av hepariner med lav molekylvekt for fremstilling av et medikament for terapi av cerebrale odemer Download PDF

Info

Publication number: NO317003B1
Authority: NO; Norway
Prior art keywords: molecular weight; low molecular; heparin; lesion; weight heparins
Prior art date: 1997-05-28

Application number

NO19995539A

Other languages

English (en)

Norwegian (no)

Other versions

NO995539D0 (no

NO995539L (no

Inventor

Andre Uzan

Jean-Marie Stutzmann

Florence Wahl

Veronique Mary

Jeremy Pratt

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-28

Filing date

1999-11-12

Publication date

2004-07-19

1999-11-12 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

1999-11-12 Publication of NO995539D0 publication Critical patent/NO995539D0/no

1999-11-12 Publication of NO995539L publication Critical patent/NO995539L/no

2004-07-19 Publication of NO317003B1 publication Critical patent/NO317003B1/no

Links

229940127215 low-molecular weight heparin Drugs 0.000 title claims abstract description 35
206010048962 Brain oedema Diseases 0.000 title claims abstract description 10
208000006752 brain edema Diseases 0.000 title claims abstract description 8
239000003814 drug Substances 0.000 title claims description 5
238000002560 therapeutic procedure Methods 0.000 title claims description 4
229940079593 drug Drugs 0.000 title description 4
238000004519 manufacturing process Methods 0.000 title description 2
239000003055 low molecular weight heparin Substances 0.000 claims abstract description 16
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 28
229920000669 heparin Polymers 0.000 claims description 19
229960002897 heparin Drugs 0.000 claims description 11
229960000610 enoxaparin Drugs 0.000 claims description 6
-1 heparin ester Chemical class 0.000 claims description 5
229960000899 nadroparin Drugs 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
229940090880 ardeparin Drugs 0.000 claims description 2
229940107792 certoparin Drugs 0.000 claims description 2
229960003828 danaparoid Drugs 0.000 claims description 2
XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 claims description 2
229920001542 oligosaccharide Polymers 0.000 claims description 2
150000002482 oligosaccharides Chemical class 0.000 claims description 2
229960005496 reviparin Drugs 0.000 claims description 2
229960005062 tinzaparin Drugs 0.000 claims description 2
229960004762 parnaparin Drugs 0.000 claims 1
230000003902 lesion Effects 0.000 description 25
206010030113 Oedema Diseases 0.000 description 14
241001465754 Metazoa Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000000203 mixture Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
230000002490 cerebral effect Effects 0.000 description 6
241000700159 Rattus Species 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000003625 skull Anatomy 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
210000001320 hippocampus Anatomy 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000013222 sprague-dawley male rat Methods 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007799 cork Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
210000001951 dura mater Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000000034 method Methods 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
229930187593 rose bengal Natural products 0.000 description 2
AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 2
229940081623 rose bengal Drugs 0.000 description 2
STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009424 thromboembolic effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010038669 Respiratory arrest Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001858 anti-Xa Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007547 defect Effects 0.000 description 1
239000003479 dental cement Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000002874 effect on oedema Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000008141 laxative Substances 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229940118179 lovenox Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000009527 percussion Methods 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
HFFLGKNGCAIQMO-UHFFFAOYSA-N trichloroacetaldehyde Chemical compound ClC(Cl)(Cl)C=O HFFLGKNGCAIQMO-UHFFFAOYSA-N 0.000 description 1
239000002966 varnish Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
208000003663 ventricular fibrillation Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

NO19995539A 1997-05-28 1999-11-12 Anvendelse av hepariner med lav molekylvekt for fremstilling av et medikament for terapi av cerebrale odemer NO317003B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9706551A FR2763849B1 (fr)	1997-05-28	1997-05-28	Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux
PCT/FR1998/001035 WO1998053834A1 (fr)	1997-05-28	1998-05-25	Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement des oedemes cerebraux

Publications (3)

Publication Number	Publication Date
NO995539D0 NO995539D0 (no)	1999-11-12
NO995539L NO995539L (no)	1999-11-12
NO317003B1 true NO317003B1 (no)	2004-07-19

Family

ID=9507336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19995539A NO317003B1 (no)	1997-05-28	1999-11-12	Anvendelse av hepariner med lav molekylvekt for fremstilling av et medikament for terapi av cerebrale odemer

Country Status (24)

Country	Link
US (1)	US6579858B1 (es)
EP (1)	EP0984787B1 (es)
JP (1)	JP2002502387A (es)
KR (1)	KR100562425B1 (es)
CN (1)	CN1223351C (es)
AT (1)	ATE225181T1 (es)
AU (1)	AU742995B2 (es)
BR (1)	BR9809180A (es)
CA (1)	CA2290682A1 (es)
DE (1)	DE69808455T2 (es)
DK (1)	DK0984787T3 (es)
ES (1)	ES2182321T3 (es)
FR (1)	FR2763849B1 (es)
IL (2)	IL132670A0 (es)
MA (1)	MA24554A1 (es)
NO (1)	NO317003B1 (es)
NZ (1)	NZ501366A (es)
PE (1)	PE73099A1 (es)
PT (1)	PT984787E (es)
RU (1)	RU2195287C2 (es)
TN (1)	TNSN98072A1 (es)
TW (1)	TW546141B (es)
WO (1)	WO1998053834A1 (es)
ZA (1)	ZA984433B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2787329B1 (fr) *	1998-12-17	2001-02-09	Aventis Pharma Sa	Nouvelle application therapeutique des heparines de bas poids moleculaire
CA2458852A1 (en) *	2001-08-28	2003-03-06	Leo Pharma A/S	Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate
ITMI20031023A1 (it) *	2003-05-21	2004-11-22	Umberto Cornelli	Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
US11840565B2 (en)	2016-12-29	2023-12-12	University Of Miami	Methods and compositions for treating virus-associated inflammation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2013092C1 (ru) *	1989-02-27	1994-05-30	Дагестанский государственный медицинский институт	Способ лечения отека мозга при туберкулезном менингоэнцефалите

1997
- 1997-05-28 FR FR9706551A patent/FR2763849B1/fr not_active Expired - Fee Related
1998
- 1998-05-19 PE PE1998000385A patent/PE73099A1/es not_active Application Discontinuation
- 1998-05-25 AU AU77760/98A patent/AU742995B2/en not_active Ceased
- 1998-05-25 EP EP98925774A patent/EP0984787B1/fr not_active Expired - Lifetime
- 1998-05-25 IL IL13267098A patent/IL132670A0/xx unknown
- 1998-05-25 JP JP50031199A patent/JP2002502387A/ja not_active Ceased
- 1998-05-25 DE DE69808455T patent/DE69808455T2/de not_active Expired - Lifetime
- 1998-05-25 BR BR9809180-8A patent/BR9809180A/pt not_active Application Discontinuation
- 1998-05-25 NZ NZ501366A patent/NZ501366A/xx unknown
- 1998-05-25 MA MA25089A patent/MA24554A1/fr unknown
- 1998-05-25 ES ES98925774T patent/ES2182321T3/es not_active Expired - Lifetime
- 1998-05-25 AT AT98925774T patent/ATE225181T1/de not_active IP Right Cessation
- 1998-05-25 PT PT98925774T patent/PT984787E/pt unknown
- 1998-05-25 RU RU99128103/14A patent/RU2195287C2/ru not_active IP Right Cessation
- 1998-05-25 DK DK98925774T patent/DK0984787T3/da active
- 1998-05-25 ZA ZA984433A patent/ZA984433B/xx unknown
- 1998-05-25 KR KR1019997011052A patent/KR100562425B1/ko not_active IP Right Cessation
- 1998-05-25 TW TW087108064A patent/TW546141B/zh not_active IP Right Cessation
- 1998-05-25 CN CNB988054906A patent/CN1223351C/zh not_active Expired - Fee Related
- 1998-05-25 CA CA002290682A patent/CA2290682A1/fr not_active Abandoned
- 1998-05-25 WO PCT/FR1998/001035 patent/WO1998053834A1/fr active IP Right Grant
- 1998-05-27 TN TNTNSN98072A patent/TNSN98072A1/fr unknown
1999
- 1999-11-01 IL IL132670A patent/IL132670A/en not_active IP Right Cessation
- 1999-11-12 NO NO19995539A patent/NO317003B1/no not_active IP Right Cessation
- 1999-11-29 US US09/450,110 patent/US6579858B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6579858B1 (en)	2003-06-17
NZ501366A (en)	2000-11-24
EP0984787A1 (fr)	2000-03-15
DE69808455D1 (de)	2002-11-07
DK0984787T3 (da)	2003-02-03
FR2763849A1 (fr)	1998-12-04
IL132670A0 (en)	2001-03-19
CA2290682A1 (fr)	1998-12-03
KR20010013073A (ko)	2001-02-26
CN1223351C (zh)	2005-10-19
ES2182321T3 (es)	2003-03-01
CN1257429A (zh)	2000-06-21
WO1998053834A1 (fr)	1998-12-03
FR2763849B1 (fr)	2000-09-15
IL132670A (en)	2010-05-31
ATE225181T1 (de)	2002-10-15
DE69808455T2 (de)	2003-07-03
EP0984787B1 (fr)	2002-10-02
JP2002502387A (ja)	2002-01-22
NO995539D0 (no)	1999-11-12
NO995539L (no)	1999-11-12
KR100562425B1 (ko)	2006-03-17
PT984787E (pt)	2003-01-31
AU742995B2 (en)	2002-01-17
RU2195287C2 (ru)	2002-12-27
BR9809180A (pt)	2000-08-01
TNSN98072A1 (fr)	2005-03-15
ZA984433B (en)	1998-12-28
TW546141B (en)	2003-08-11
MA24554A1 (fr)	1998-12-31
PE73099A1 (es)	1999-10-21
AU7776098A (en)	1998-12-30

Publication	Publication Date	Title
JP2806454B2 (ja)	1998-09-30	脈管形成阻止剤
DE69831421T2 (de)	2006-06-22	Zusammensetzungen zur nasalen verabreichung
AU2004224510B2 (en)	2009-12-03	Remedy for nerve damage
CA2100197A1 (en)	1994-02-01	Use of polysaccharides in acute peripheral neuropathies
NO317003B1 (no)	2004-07-19	Anvendelse av hepariner med lav molekylvekt for fremstilling av et medikament for terapi av cerebrale odemer
HUT76895A (en)	1997-12-29	Use of hyaluronic acid for preparing pharmaceutical compns. for treatment of disease and conditions associated with macrophage infiltration
NO317517B1 (no)	2004-11-08	Anvendelse av hepariner med lav molekylvekt for fremstilling av medikamenter for terapi av sentralnervesystemtrauma
CA2868403A1 (en)	2013-11-14	Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
MXPA99010595A (es)	2000-09-04	Uso de las heparinas de bajo peso molecular para la prevención y tratamiento de los edemas cerebrales
US20230074200A1 (en)	2023-03-09	Method for treating botulinum toxin poisoning
IT202100027047A1 (it)	2023-04-21	Composizione eterogenea a fasi stratificate di acido ialuronico e suo uso intrarticolare
NZ517119A (en)	2003-11-28	Use of low-molecular-weight heparins for preventing and treating central nervous system (CNS) trauma

Legal Events

Date	Code	Title	Description
2010-12-27	MM1K	Lapsed by not paying the annual fees